Trials / Completed
CompletedNCT00905047
Xeloda or UFT (Tegafur-uracil) With Folinic Acid in Advanced or Metastatic Colorectal Cancer
Open Comparative Study With a Cross-over According to Patients'Preference Receiving Xeloda or UFT With Folinic Acid in Advanced or Metastatic Colo-rectal Cancer
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 89 (actual)
- Sponsor
- Centre Oscar Lambret · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The scope of the trial is to determine the preference of patients, after randomization and cross-over, for one of the two treatments. Another objective of the trial is to assess and compare the safety of each treatment.
Detailed description
Further study details as provided by Centre Oscar Lambret.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XELODA | XELODA, 2500 mg/m²/bid, with approximatively an interval of 12 hours, 30 minutes after breakfast and dinner - during 14 days. Cycle treatment duration : 21 days |
| DRUG | TEGAFUR URACIL - FOLINIC ACID | Tegafur 300 mg/m2/tid with folinic acid 75 mg/tid during 28 days. Duration of treatment cycle : 35 days. |
Timeline
- Start date
- 2005-11-14
- Primary completion
- 2010-06-01
- Completion
- 2011-09-01
- First posted
- 2009-05-20
- Last updated
- 2026-03-13
Locations
13 sites across 1 country: France
Source: ClinicalTrials.gov record NCT00905047. Inclusion in this directory is not an endorsement.